



#16158
5/22/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GROSSMAN ET AL.

Examiner: LOEB, B.

Art Unit: 1636

Application No.: 09/596,114

Filed: JUNE 16, 2000

Title: **NOVEL VECTORS FOR IMPROVING
CLONING AND EXPRESSION IN LOW
COPY NUMBER PLASMIDS**

COPY OF PAPER
ORIGINALLY FILED

TECH CENTER 1600/2908

MAY 20 2002

RECEIVED


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In furtherance of their duty under 37 C.F.R. 1.56, Applicants submit herewith additional patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Respectfully submitted,


William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
May 6, 2002
Aventis Docket No. HMR2050